These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34356910)

  • 21. Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention.
    Fischer A; Patel NM; Volkmann ER
    Open Access Rheumatol; 2019; 11():283-307. PubMed ID: 31849543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease.
    Valenzi E; Bulik M; Tabib T; Morse C; Sembrat J; Trejo Bittar H; Rojas M; Lafyatis R
    Ann Rheum Dis; 2019 Oct; 78(10):1379-1387. PubMed ID: 31405848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement.
    Trombetta AC; Soldano S; Contini P; Tomatis V; Ruaro B; Paolino S; Brizzolara R; Montagna P; Sulli A; Pizzorni C; Smith V; Cutolo M
    Respir Res; 2018 Sep; 19(1):186. PubMed ID: 30249259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring the common pathophysiological links between IPF, SSc-ILD and post-COVID fibrosis.
    Swarnakar R; Garje Y; Markandeywar N; Mehta S
    Lung India; 2022; 39(3):279-285. PubMed ID: 35488687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Four Corners Sign: A Specific Imaging Feature in Differentiating Systemic Sclerosis-related Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis.
    Walkoff L; White DB; Chung JH; Asante D; Cox CW
    J Thorac Imaging; 2018 May; 33(3):197-203. PubMed ID: 29346191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Potential ceRNA Network and Patterns of Immune Cell Infiltration in Systemic Sclerosis-Associated Interstitial Lung Disease.
    Wu Q; Liu Y; Xie Y; Wei S; Liu Y
    Front Cell Dev Biol; 2021; 9():622021. PubMed ID: 34222222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand?
    Elhai M; Avouac J; Allanore Y
    Semin Arthritis Rheum; 2020 Jun; 50(3):480-491. PubMed ID: 32089354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis.
    Yamakawa H; Hagiwara E; Kitamura H; Yamanaka Y; Ikeda S; Sekine A; Baba T; Iso S; Okudela K; Iwasawa T; Takemura T; Kuwano K; Ogura T
    PLoS One; 2016; 11(8):e0161908. PubMed ID: 27564852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-155 in the progression of lung fibrosis in systemic sclerosis.
    Christmann RB; Wooten A; Sampaio-Barros P; Borges CL; Carvalho CR; Kairalla RA; Feghali-Bostwick C; Ziemek J; Mei Y; Goummih S; Tan J; Alvarez D; Kass DJ; Rojas M; de Mattos TL; Parra E; Stifano G; Capelozzi VL; Simms RW; Lafyatis R
    Arthritis Res Ther; 2016 Jul; 18(1):155. PubMed ID: 27377409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Automatic Quantification of Interstitial Lung Disease From Chest Computed Tomography in Systemic Sclerosis.
    Carvalho ARS; Guimarães AR; Sztajnbok FR; Rodrigues RS; Silva BRA; Lopes AJ; Zin WA; Almeida I; França MM
    Front Med (Lausanne); 2020; 7():577739. PubMed ID: 33102508
    [No Abstract]   [Full Text] [Related]  

  • 32. CEACAM 1, 3, 5 and 6 -positive classical monocytes correlate with interstitial lung disease in early systemic sclerosis.
    Yokoyama K; Mitoma H; Kawano S; Yamauchi Y; Wang Q; Ayano M; Kimoto Y; Ono N; Arinobu Y; Akashi K; Horiuchi T; Niiro H
    Front Immunol; 2022; 13():1016914. PubMed ID: 36341379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
    Atanelishvili I; Akter T; Noguchi A; Vuyiv O; Wollin L; Silver RM; Bogatkevich GS
    Clin Exp Rheumatol; 2019; 37 Suppl 119(4):115-124. PubMed ID: 31573469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease.
    Hoffmann-Vold AM; Weigt SS; Saggar R; Palchevskiy V; Volkmann ER; Liang LL; Ross D; Ardehali A; Lynch JP; Belperio JA
    EBioMedicine; 2019 Dec; 50():379-386. PubMed ID: 31732480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
    de Lauretis A; Veeraraghavan S; Renzoni E
    Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease - frontiers and horizons.
    Jee AS; Sahhar J; Youssef P; Bleasel J; Adelstein S; Nguyen M; Corte TJ
    Pharmacol Ther; 2019 Oct; 202():40-52. PubMed ID: 31153954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated VCAM-1, MCP-1 and ADMA serum levels related to pulmonary fibrosis of interstitial lung disease associated with rheumatoid arthritis.
    Pulito-Cueto V; Remuzgo-Martínez S; Genre F; Atienza-Mateo B; Mora-Cuesta VM; Iturbe-Fernández D; Lera-Gómez L; Sebastián Mora-Gil M; Prieto-Peña D; Portilla V; Blanco R; Corrales A; Ocejo-Vinyals JG; Gualillo O; Ferraz-Amaro I; Cifrián JM; López-Mejías R; González-Gay MA
    Front Mol Biosci; 2022; 9():1056121. PubMed ID: 36601584
    [No Abstract]   [Full Text] [Related]  

  • 38. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
    van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
    Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interstitial lung disease in systemic sclerosis.
    Bussone G; Mouthon L
    Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
    Volkmann ER; Tashkin DP; Roth MD; Clements PJ; Khanna D; Furst DE; Mayes M; Charles J; Tseng CH; Elashoff RM; Assassi S
    Arthritis Res Ther; 2016 Dec; 18(1):305. PubMed ID: 28038680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.